protocolSection identificationModule nctId: NCT06327308, orgStudyIdInfo id: 2023/803, briefTitle: Evaluation of Cirrhotic Cardiomyopathy by Cardiac MRI in Patients Waiting for Liver Transplant., acronym: CARDIOFIBROCIR, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-31, primaryCompletionDateStruct date: 2025-03-31, completionDateStruct date: 2027-12-31, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: Centre Hospitalier Universitaire de Besancon, class: OTHER, descriptionModule briefSummary: The aim of this multicenter prospective observational pilot study is to describe the evolution of myocardial fibrosis in cirrhotic patients before and after liver transplantation (LT). Through multimodal analysis of myocardial function and architecture, and analysis of specific markers of inflammation, we aim to explore the following hypotheses: 1) systemic inflammation promotes myocardial fibrosis in cirrhotic patients and could be an early marker of cirrhotic cardiomyopathy; 2) LT allows resolution of myocardial fibrosis by preventing the bacterial translocation that favors the development of deleterious systemic inflammation., conditionsModule conditions: Cirrhosis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: MRI, interventions name: Blood sampling, outcomesModule primaryOutcomes measure: Primary outcome measure, secondaryOutcomes measure: Prevalence of cirrhotic cardiomyopathy according to 2019 criteria [Izzy M, et al. Hepatology 2020;71:334-45], echocardiographic signs of left ventricular systolic and diastolic dysfunction :, secondaryOutcomes measure: Analysis of the association between myocardial extracellular volume (MECV) (explained variable) and plasma 3-HM concentration (explanatory variable)., secondaryOutcomes measure: Analysis of the association between myocardial extracellular volume (MECV) and the concentration of markers of inflammation (CRP, procalcitonin, copeptin, IL-6) and proteins modulating the degree of inflammation (LBP, PLTP, CETP)., secondaryOutcomes measure: Analysis of the association between the difference in MECV in transplant recipients between visit 2 and visit 3 according to the degree of immunosuppression, measured by mean residual tacrolemia in the 12 months post-LT., secondaryOutcomes measure: Number, type and cumulative incidence of cardiovascular events (heart failure, rhythm disorders, etc.) according to cirrhotic cardiomyopathy status occurring between inclusion and LT., secondaryOutcomes measure: Number, type and cumulative incidence of cardiovascular events (heart failure, rhythm disorders, etc.) occurring between inclusion and LT, according to cirrhotic cardiomyopathy status., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: CHU Besancon - Hopital Minjoz, city: Besançon, zip: 25000, country: France, contacts name: Delphine WEIL, MD, PHD, role: CONTACT, geoPoint lat: 47.24878, lon: 6.01815, locations facility: CHU Dijon - Hopital François Mitterrand, city: Dijon, zip: 21000, country: France, contacts name: Marianne LATOURNERIE, MD, role: CONTACT, geoPoint lat: 47.31667, lon: 5.01667, locations facility: CHRU Nancy - Hôpital de Brabois, city: Nancy, zip: 54000, country: France, contacts name: Mouni BENSENANE -OUSSALAH, MD, role: CONTACT, geoPoint lat: 48.68439, lon: 6.18496, locations facility: CHU Strasbourg - Hopital de HautePierre, city: Strasbourg, zip: 67000, country: France, contacts name: Camille BESCH, MD, role: CONTACT, geoPoint lat: 48.58392, lon: 7.74553, hasResults: False